Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report.

Autor: Peng, Sujuan1 (AUTHOR), Huang, Hongxiang1 (AUTHOR), Zhu, Xie1 (AUTHOR), Chen, Jinhong1 (AUTHOR), Ding, Xinjing1 (AUTHOR), Wang, Fen1 (AUTHOR), Chen, Li1 (AUTHOR) ndyfy01985@ncu.edu.cn, Lu, Zhihui1 (AUTHOR) ndyfy01985@ncu.edu.cn
Zdroj: Experimental & Therapeutic Medicine. May2024, Vol. 27 Issue 5, pN.PAG-N.PAG. 1p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje